Compounds > win 53338
Page last updated: 2024-12-04

win 53338

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

WIN 53338: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole : An isoxazole compound having a methyl substituent at the 3-position and a 5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl substituent at the 5-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1788
CHEMBL ID6444
CHEBI ID47727
SCHEMBL ID9666735
MeSH IDM0202242

Synonyms (23)

Synonym
win 53338
isoxazole, 5-[5-[2-chloro-4-(4,5-dihydro-2-oxazolyl)phenoxy]pentyl]-3-methyl-
5-[5-[2-chloro-4-(4,5-dihydrooxazol-2-yl)phenoxy]pentyl]-3-methyl-isoxazole
98033-68-2
5-(5-(6-chloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-methylisoxazole
C06489
compound vii
5-(5-(6-chloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole
DB08719
5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole
win-53338
CHEBI:47727 ,
CHEMBL6444
ivz08daw25 ,
win53338
unii-ivz08daw25
isoxazole, 5-(5-(2-chloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-methyl-
SCHEMBL9666735
DTXSID50913499
5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methyl-1,2-oxazole
5-(5-(2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy)pentyl)-3-methyl-1,2-oxazole
Q27097904
PD004183
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antiviral agentA substance that destroys or inhibits replication of viruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
isoxazolesOxazoles in which the N and O atoms are adjacent.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID222916In vitro minimum inhibitory concentration for the inhibition of human rhinovirus-14 replication.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
A model for compounds active against human rhinovirus-14 based on X-ray crystallography data.
AID228805Tested for antirhinoviral activity against the rhinovirus serotype 891987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID228787Tested for antirhinoviral activity against the rhinovirus serotype 221987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID23485Partition coefficient (logP)1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID23690Partition coefficient (logP)1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
CoMFA analysis of the interactions of antipicornavirus compounds in the binding pocket of human rhinovirus-14.
AID228797Tested for antirhinoviral activity against the rhinovirus serotype 501987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID85207Negative logarithm of minimal inhibitory concentration against human rhinovirus 141993Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1
On the prediction of binding properties of drug molecules by comparative molecular field analysis.
AID228778Tested for antirhinoviral activity against the rhinovirus serotype 1A1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID228774Tested for antirhinoviral activity against the rhinovirus serotype 141987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID228803Tested for antirhinoviral activity against the rhinovirus serotype 861987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID84901Antiviral activity determined by ability to inhibit the HRV-2( human rhinovirus type -2) virus by plaque reduction assay in vitro1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID228795Tested for antirhinoviral activity against the rhinovirus serotype 411987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID228799Tested for antirhinoviral activity against the rhinovirus serotype 61987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID84720Compound was tested for minimum inhibitory concentration against human rhinovirus 14 (HRV14)1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Modeling RNA-ligand interactions: the Rev-binding element RNA-aminoglycoside complex.
AID228793Tested for antirhinoviral activity against the rhinovirus serotype 301987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID228801Tested for antirhinoviral activity against the rhinovirus serotype 671987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID228780Tested for antirhinoviral activity against the rhinovirus serotype 1B1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID84907Antirhinovirus activity was assessed and the maximum testable concentration that causes no apparent effects on the cell monolayers was determined against HRV-2 virus in vitro.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID228790Tested for antirhinoviral activity against the rhinovirus serotype 251987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID222913Mean of MIC's was determined for the five types of virus like HRV-2, HRV-1A,HRV-22,HRV-41 and HRV-501987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID26042log (1/MIC) value of the compound1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
CoMFA analysis of the interactions of antipicornavirus compounds in the binding pocket of human rhinovirus-14.
AID228783Tested for antirhinoviral activity against the rhinovirus serotype 21987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID89493Compound was evaluated for inhibitory effect against human Rhinovirus-141992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
CoMFA analysis of the interactions of antipicornavirus compounds in the binding pocket of human rhinovirus-14.
AID228776Tested for antirhinoviral activity against the rhinovirus serotype 151987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID84903Antirhinovirus activity was determined by the ability to inhibit the HRV-2 virus growth by 80%1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
AID228785Tested for antirhinoviral activity against the rhinovirus serotype 211987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's6 (85.71)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.01 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
win 52035
Win 52035: structure given in first source		3.0850aromatic ether
win 52084
Win 52084: structure given in first source; RN given refers to (+-)-isomer; RN for cpd without isomeric designation not available 7/89		2.3820aromatic ether
leucine
Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.		2.3820amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		2.3820L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
framycetin
Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.		1.9910aminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite
oxazoles
Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.		2.38201,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
ribostamycin
Ribostamycin: A broad-spectrum antimicrobial isolated from Streptomyces ribosifidicus.. ribostamycin : An amino cyclitol glycoside that is 4,6-diaminocyclohexane-1,2,3-triol having a 2,6-diamino-2,6-dideoxy-alpha-D-glucosyl residue attached at position 1 and a beta-D-ribosyl residue attached at position 2. It is an antibiotic produced by Streptomyces ribosidificus (formerly S. thermoflavus).		1.9910amino cyclitol glycoside;
aminoglycoside antibiotic		antibacterial drug;
antimicrobial agent;
metabolite
sisomicin
Sisomicin: Antibiotic produced by Micromonospora inyoensis. It is closely related to gentamicin C1A, one of the components of the gentamicin complex (GENTAMICINS).		1.9910amino cyclitol glycoside;
aminoglycoside antibiotic;
beta-L-arabinoside;
monosaccharide derivative
tobramycin
Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.		1.9910amino cyclitol glycosideantibacterial agent;
antimicrobial agent;
toxin
disoxaril
disoxaril: antipicornavirus agent		2.8940aromatic ether
neamine
neamine: fragment of NEOMYCIN B; structure in first source. neamine : 2-Deoxy-D-streptamine glycosylated at the 4-oxygen with a 6-amino-alpha-D-glucosaminyl group.		1.99102,6-dideoxy-alpha-D-glucoside;
aminoglycoside		antibacterial agent
lividomycin
[no description available]		1.9910lividomycinsmetabolite
paromomycin
Paromomycin: An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES.. paromomycin : An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.		1.9910amino cyclitol glycoside;
aminoglycoside antibiotic		anthelminthic drug;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
bekanamycin
bekanamycin: kanendomycin is the sulfate of bekanamycin; RN given refers to parent cpd; structure		1.9910kanamycins
win 54954
Win 54954: broad-spectrum antipicornavirus drug; structure given in first source		1.9810aromatic ether
ConditionIndicatedRelationship StrengthStudiesTrials